IBSA PHARMA LIMITED
Get an alert when IBSA PHARMA LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2027-09-30 (in 1y)
Last filed for 2025-12-31
Confirmation statement due
2027-03-07 (in 10mo)
Last made up 2026-02-21
Watchouts
None on the register
Cash
£3M
-20.2% vs 2024
Net assets
£8M
+5.2% vs 2024
Employees
49
+22.5% vs 2024
Profit before tax
£555K
-38.9% vs 2024
Net assets
7-year trend · vs Consumer Discretionary median
Accounts
7-year trend · latest reflected 2025-12-31
| Metric | Trend | 2020-02-29 | 2021-02-28 | 2022-02-28 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|---|
| Turnover | — | — | — | — | — | £20,454,359 | £22,525,632 | |
| Operating profit | — | — | — | — | — | £785,021 | £467,433 | |
| Profit before tax | — | — | — | — | — | £908,373 | £555,271 | |
| Net profit | — | — | — | — | — | £673,371 | £411,883 | |
| Cash | — | — | — | — | — | £4,303,226 | £3,434,401 | |
| Total assets less current liabilities | — | — | — | — | — | £7,969,326 | £8,389,260 | |
| Net assets | — | — | — | — | — | £7,918,024 | £8,329,907 | |
| Equity | — | — | — | — | — | £7,918,024 | £8,329,907 | |
| Average employees | — | — | — | — | — | 40 | 49 | |
| Wages | — | — | — | — | — | £2,274,954 | £3,008,116 | |
| Directors' remuneration | — | — | — | — | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2024 → FY2025 · period ending 2025-12-31 vs 2024-12-31
-
Turnover
+10.1%
£20,454,359 £22,525,632
-
Cash
-20.2%
£4,303,226 £3,434,401
-
Net assets
+5.2%
£7,918,024 £8,329,907
-
Employees
+22.5%
40 49
-
Operating profit
-40.5%
£785,021 £467,433
-
Profit before tax
-38.9%
£908,373 £555,271
-
Wages
+32.2%
£2,274,954 £3,008,116
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2020-02-29 | 2021-02-28 | 2022-02-28 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | — | — | — | — | — | 3.8% | 2.1% | |
| Net margin | — | — | — | — | — | 3.3% | 1.8% | |
| Return on capital employed | — | — | — | — | — | 9.9% | 5.6% | |
| Current ratio | — | — | — | — | — | 2.47x | 3.06x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- IBSA PHARMA LIMITED 2023-01-11 → present
- PHARMASURE LIMITED 2000-02-21 → 2023-01-11
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Rödl & Partner Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.”
Significant events
- “In 2025, IBSA Pharma continues to adopt the IBSA Group strategy to have a direct presence in markets across different therapeutic arcas.”
- “The company has entered into a liability limitation agreement with the company's auditor which was approved on 14th July 2025.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 9 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| GRASSI, Luca, Mr. | Director | 2022-05-05 | Sep 1970 | Italian |
| LICENZIATI, Arturo, Dr. | Director | 2022-05-05 | Apr 1935 | Swiss |
| RACCA, Elisabetta | Director | 2023-06-30 | Jun 1969 | Italian |
Show 9 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| HILL, Kenneth | Secretary | 2000-02-21 | 2001-01-31 |
| SULLIVAN, Terence | Secretary | 2001-01-31 | 2022-05-05 |
| COMBINED SECRETARIAL SERVICES LIMITED | Corporate Nominee Secretary | 2000-02-21 | 2000-02-21 |
| HILL, Kenneth | Director | 2000-02-21 | 2001-02-19 |
| MELLI, Antonio, Mr. | Director | 2022-05-05 | 2025-09-30 |
| SULLIVAN, Christine Olga | Director | 2000-02-21 | 2022-05-05 |
| SULLIVAN, Terence | Director | 2007-03-01 | 2022-05-05 |
| COMBINED NOMINEES LIMITED | Corporate Nominee Director | 2000-02-21 | 2000-02-21 |
| COMBINED SECRETARIAL SERVICES LIMITED | Corporate Nominee Director | 2000-02-21 | 2000-02-21 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Dr. Arturo Licenziati | Individual | Shares 75–100%, Voting 75–100% | 2022-05-05 | Active |
| Mr Terence Sullivan | Individual | Shares 75–100%, Voting 25–50% | 2016-04-06 | Ceased 2022-05-05 |
| Mrs Christine Olga Sullivan | Individual | Shares 75–100%, Voting 25–50% | 2016-04-06 | Ceased 2022-05-05 |
Filing timeline
Last 20 of 97 total filings
Material constitutional events — rename, articles re-file, resolution
- 2023-01-23 RESOLUTIONS Resolution
- 2023-01-11 CERTNM Certificate change of name company PDF
- 2022-11-28 MA Memorandum articles
- 2022-11-28 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-02-16 | AA | accounts | Accounts with accounts type full | |
| 2025-10-10 | TM01 | officers | Termination director company with name termination date | |
| 2025-02-25 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-02-13 | AA | accounts | Accounts with accounts type full | |
| 2024-04-12 | AA | accounts | Accounts with accounts type full | |
| 2024-02-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-07-03 | AP01 | officers | Appoint person director company with name date | |
| 2023-04-03 | AA | accounts | Accounts with accounts type full | |
| 2023-02-22 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-01-23 | RESOLUTIONS | resolution | Resolution | |
| 2023-01-11 | CERTNM | change-of-name | Certificate change of name company | |
| 2022-11-28 | MA | incorporation | Memorandum articles | |
| 2022-11-28 | RESOLUTIONS | resolution | Resolution | |
| 2022-10-14 | AA | accounts | Accounts with accounts type full | |
| 2022-10-07 | SH08 | capital | Capital name of class of shares | |
| 2022-05-09 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2022-05-09 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2022-05-09 | PSC01 | persons-with-significant-control | Notification of a person with significant control | |
| 2022-05-06 | AA01 | accounts | Change account reference date company current shortened |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.